Mizuho Securities analyst maintained a Buy rating on Assembly Biosciences ( – ) today and set a price target of $3.00. The company’s shares opened today at $1.53.Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to , Syed has an average return of -10.9% and a 43.14% success rate on recommended stocks.Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.The company has a one-year high of $2.42 and a one-year low of $0.82. Currently, Assembly Biosciences has an average volume of 321.9K.TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which are most likely to make moves following th

$Assembly Biosciences Inc.(ASMB)$ Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic toxicology observation for ABI-H3733Phase 1a complete clinical data for all ABI-4334 dose cohorts expected in April 2023Advancing expanded research portfolio, with additional development candidate nomination anticipated in 2023 and IND/CTA submission for herpesvirus candidate ABI-5366 planned for the first half of 2024SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious

$Assembly Biosciences Inc.(ASMB)$?16.08  ⚠️

Assembly Biosciences (ASMB) Gets a Buy from Mizuho Securities